Former Shire execs set up shop to take a shot at 'under the radar' cancer target
In December 2016, Shire abandoned a cancer drug targeting oxMIF it had swallowed as part of its $32 billion buyout of Baxalta earlier that year. Now former executives of the two companies have set up their own shop in Austria — banking on that same target.
The company, christened OncoOne, has scored €13 million in a Series A round. With 8 employees, including its 3 founders, the company will use the injection to take its compounds — designed to address pancreatic, colorectal, lung and ovarian cancer — into the clinic by 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.